DENVER, Colo. (247marketnews.com) -- Creative Medical (NASDAQ:CELZ) could remain one to watch after attracting investor attention following yesterday’s reaction to news that the U.S. Patent and Trademark Office issued a Notice of Allowance for a new patent covering its exosome-based immunotherapy platform targeting Type 1 diabetes. The announcement added another layer of intellectual property protection to the company's expanding regenerative medicine portfolio and highlighted its strategy of building multiple therapeutic approaches aimed at one of the largest unmet needs in autoimmune disease.
The newly allowed patent protects Creative Medical's MyeloCelz™ technology, a cell-free exosome platform designed to suppress the autoimmune attack responsible for destroying insulin-producing pancreatic beta cells. Unlike conventional therapies focused primarily on managing blood glucose, the platform is designed to promote antigen-specific immune tolerance while preserving the broader immune system. The patent also covers combinations with antibodies, cellular therapies, and small molecules, potentially expanding future development opportunities.
The latest allowance further strengthens what has become an increasingly diversified diabetes franchise. Creative Medical is advancing CELZ-201 (AlloStem®) in the FDA-cleared CREATE-1 clinical trial for newly diagnosed Type 1 diabetes, while CELZ-101 (ImmCelz®) has received FDA Orphan Drug Designation for use alongside pancreatic islet transplantation in brittle Type 1 diabetes. Together with the MyeloCelz™ platform and its Type 2 diabetes program, the company is pursuing multiple scientific pathways designed to address different stages and mechanisms of disease rather than relying on a single therapeutic candidate.
The expanding intellectual property portfolio may also enhance the company's long-term strategic flexibility. Following formal issuance of the patent, Creative Medical plans to continue expanding its exosome-related patent estate while advancing ongoing clinical programs and evaluating potential licensing and partnership opportunities across its diabetes platforms. The company now reports an intellectual property portfolio consisting of approximately 60 issued patents and pending applications spanning regenerative medicine, immunology, endocrinology, and other therapeutic areas.
CELZ’s current trigger point is $1.44 and support at $1.22.
With approximately 2.1 million Americans living with Type 1 diabetes and no approved cure currently available, investor attention is likely to remain focused on companies developing disease-modifying therapies rather than incremental improvements to insulin management. After yesterday's positive market response, traders may continue watching CELZ for additional catalysts as the company advances its clinical programs, expands its patent portfolio, and works to build value across its regenerative medicine pipeline.
Sources
Creative Medical Technology Holdings: https://creativemedicaltechnology.com/
U.S. Patent and Trademark Office (USPTO): https://www.uspto.gov/
U.S. Centers for Disease Control and Prevention – Type 1 Diabetes: https://www.cdc.gov/diabetes/
SEC Filings – Creative Medical (NASDAQ: CELZ): https://www.sec.gov/edgar/search/
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.